More good news for Janssen’s Darzalex
admin 11th December 2019 Uncategorised 0The drug has hit survival and disease progression targets in Phase III trials More: More good news for Janssen’s Darzalex Source: News
read moreThe drug has hit survival and disease progression targets in Phase III trials More: More good news for Janssen’s Darzalex Source: News
read moreChildren with cystic fibrosis as young as six months with certain mutations can now access the treatment More: EU expands scope of Vertex’ Kalydeco Source: News
read moreThe main reason for not sharing DNA for drug research is the fear it could be used without knowledge for corporate gain More: EXCLUSIVE: Brits back sharing DNA for research Source: News
read moreWhen Novartis unveiled its $9.7 billion buyout of The Medicines Company a few days ago, several industry watchers suggested the price was too high. Turns out, Novartis’ own number-crunching “could not justify $85 per share” for the PCSK9 drug developer,
read moreSanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab. The company has long been a leader in diabetes and cardiovascular diseases, but it won’t
read moreAfter more than a decade of working together, Sanofi and Regeneron’s drug partnership finally turned a profit recently on the back of strong sales of blockbuster Dupixent. Instead of staying the course, the couple are now reworking their arrangement—and so far
read more© 1994 - 2024 B.M. Pharmaceuticals